OUR COMMITMENT TO PATIENTS

At Spectrum Pharmaceuticals, Inc., we bring the expertise and passion for excellence of our team to acquire, develop and commercialize novel and targeted pharmaceuticals for unmet medical needs while building value for our shareholders.

More

Focused on the Future

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development. Spectrum has a late-stage pipeline that has the potential to transform the company.

Spectrum has three drugs in advanced development:

Poziotinib
Poziotinib for a mutation in Non Small Cell Lung Cancer (NSCLC), and for patients with breast cancer. Learn more »
ROLONTIS® (eflapegrastim)
ROLONTIS® (eflapegrastim), being developed for chemotherapy-induced neutropenia in patients with breast cancer. Learn more »
Apaziquone
Apaziquone for Intravesical Instillation, being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. Learn more »

Expanding Patient Options

Our passion to deliver additional options for patients suffering from cancer is behind every action we take. We will work to understand their needs and develop new and innovative therapies that offer hope for improved disease outcomes. Learn more about the Spectrum philosophy.

The Spectrum Philosophy